The first two drugs showing promise in slowing the progression of geographic atrophy are poised for FDA approval. Will this signal a new era in patient care?
The February supplement from the USC Roski Eye Institute can be found here: 2022 Annual Report.
Explore TEPEZZA® (teprotumumab-trbw) now
for your patients with this serious, progressive disease.
TEPEZZA is a trademark owned by or licensed to Horizon.
© 2022 Horizon Therapeutics plc P-TEP-US-00805 12/22